RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Sorafenib as Effective Treatment for Newly Diagnosed AML in Younger Patients
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 8
OP 9
DO 10.1177/1559897715570842
UL http://mdc.sagepub.com/content/14/55/8.2.abstract
AB Acute myeloid leukemia, a common form of leukemia with a high mortality rate, is difficult to treat. In the SORAML trial, sorafenib, a multikinase inhibitor, prolonged event-free and relapse-free survival compared with a placebo in younger patients with acute myeloid leukemia. However, this benefit was accompanied by a higher rate of infections and bleeding.